CureVac Reports Early-Stage Data for Its Coronavirus Vaccine Candidate
CureVac (NASDAQ: CVAC) is trailing the leaders in the race to develop a vaccine that can protect people from developing COVID-19. But the biotech is making progress, and now has data from an early-stage trial of its coronavirus vaccine candidate that shows the top dose it's administering appears to be having the desired effect.
In the phase 1 study of CureVac's vaccine, dubbed CvnCoV, patients who were given the highest dose being tested developed neutralizing antibodies at the same levels seen in patients who had recovered from COVID-19. Neutralizing antibodies are able to bind to the coronavirus and block it from infecting a host's cells.
Nobody in the small 250-person study suffered any serious side effects. At the highest dose tested, some participants developed fatigue, headache, chills, muscle pain, and to a lesser extent, fever, which happened mostly after the booster shot. While uncomfortable, those side effects are positive signs that the patient's immune system is launching an immune reaction to the vaccine.
Source Fool.com
